{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:45:58Z","timestamp":1790171158786,"version":"4.1.0"},"reference-count":55,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Saudi Medicine"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.4103\/0256-4947.55167","type":"journal-article","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T11:45:37Z","timestamp":1257507937000},"page":"369-377","source":"Crossref","is-referenced-by-count":87,"title":["Management of ascites due to gastrointestinal malignancy"],"prefix":"10.5144","volume":"29","author":[{"given":"Muhammad W.","family":"Saif","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A. P.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A.","family":"Sohail","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3134","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bjs.1800830104","article-title":"Malignant ascites","volume":"83","author":"Parsons SL","year":"1996","journal-title":"Br J Surg"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM199402033300508","article-title":"Care of patients with ascites","volume":"330","author":"Runyon BA","year":"1994","journal-title":"N Engl J Med"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/hep.1840080521","article-title":"Ascitic fluid analysis in malignancy-related ascites","volume":"8","author":"Runyon BA","year":"1988","journal-title":"Hepatol"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcm121","article-title":"Fluid retention in cirrhosis: pathophysiology and management","volume":"101","author":"Kashani A","year":"2008","journal-title":"QJM"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00000658-198606000-00009","article-title":"Malignant ascites. Clinical and experimental observations","volume":"203","author":"Garrison RN","year":"1986","journal-title":"Ann Surg"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0748-7983(96)80009-6","article-title":"Malignant ascites: a 2-year review from a teaching hospital","volume":"22","author":"Parsons SL","year":"1996","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore KP","year":"2003","journal-title":"Hepatol"},{"key":"e_1_3_1_9_2","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo V","year":"1996","journal-title":"International Ascites Club"},{"issue":"7","key":"e_1_3_1_10_2","first-page":"626","article-title":"Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of the Italian Association for the Study of the Liver","volume":"31","author":"Salerno F","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"22","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1001\/archinte.161.22.2733","article-title":"Malignant ascites: new concepts in pathophysiology, diagnosis, and management","volume":"161","author":"Aslam N","year":"2001","journal-title":"Arch Intern Med"},{"issue":"2","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1746.1992.tb00955.x","article-title":"Evaluation of fibronectin as a marker of malignant ascites","volume":"7","author":"Siddiqui RA","year":"1992","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1001\/archinte.161.22.2733","article-title":"Malignant ascites: new concepts in pathophysiology, diagnosis, and management","volume":"161","author":"Aslam N","year":"2001","journal-title":"Arch Intern Med"},{"issue":"5","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/dc.20279","article-title":"Malignant effusion are sources of fibronectin and other promigratory and proinvasive components","volume":"33","author":"Kohn EC","year":"2005","journal-title":"Diagn Cytopathol"},{"issue":"1","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0090-8258(92)90084-V","article-title":"Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3","volume":"47","author":"Buckman R","year":"1992","journal-title":"Gynecol Oncol"},{"key":"e_1_3_1_16_2","first-page":"1184","article-title":"Emerging indications for octreotide therapy, Part 1","volume":"51","author":"Mosdell KW","year":"1994","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1245\/s10434-007-9370-3","article-title":"The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites","volume":"14","author":"Easson AM","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Management of cirrhosis and ascites","volume":"350","author":"Gines P","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","article-title":"A survey of practice in management of malignant ascites","volume":"16","author":"Lee CW","year":"1998","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/0016-5085(92)91520-E","article-title":"Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics","volume":"103","author":"Pockros PJ","year":"1992","journal-title":"Gastroenterol"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/bjs.1800690802","article-title":"Control of malignant ascites with spironolactone","volume":"69","author":"Greenway B","year":"1982","journal-title":"Br J Surg"},{"issue":"3","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/gyno.1998.5215","article-title":"Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer","volume":"71","author":"Gotlieb WH","year":"1998","journal-title":"Gynecol Oncol"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jso.2930200411","article-title":"On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?","volume":"20","author":"Appelqvist P","year":"1982","journal-title":"J Surg Oncol"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/archinte.1979.03630390087029","article-title":"Abdominal paracentesis for malignant ascites","volume":"139","author":"Fischer DS","year":"1979","journal-title":"Arch Intern Med"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bjs.1800830104","article-title":"Malignant ascites","volume":"83","author":"Parsons SL","year":"1996","journal-title":"Br J Surg"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.gie.2005.11.058","article-title":"EUS-guided paracentesis for the diagnosis of malignant ascites","volume":"64","author":"Kaushik N","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/hep.1840050310","article-title":"The effect of large volume paracentesis on plasma volume--a cause of hypovolemia?","volume":"5","author":"Kao HW","year":"1985","journal-title":"Hepatol"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-112-12-889","article-title":"Large-volume paracentesis in treatment of ascites","volume":"112","author":"Kellerman PS","year":"1990","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_29_2","first-page":"365","article-title":"Renaissance of paracentesis in the treatment of ascites","volume":"35","author":"Reynolds TB","year":"1990","journal-title":"Adv Intern Med"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1191\/0269216302pm509oa","article-title":"The development of clinical guidelines on paracentesis for ascites related to malignancy","volume":"16","author":"Stephenson J","year":"2002","journal-title":"Palliat Med"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1191\/026921600676345896","article-title":"Paracentesis - an effective method of symptom control in the palliative care setting?","volume":"14","author":"McNamara P","year":"2000","journal-title":"Palliat Med"},{"issue":"1","key":"e_1_3_1_32_2","first-page":"709","article-title":"Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract","volume":"26","author":"Bar-Sela G","year":"2006","journal-title":"Anticancer Res"},{"issue":"2","key":"e_1_3_1_33_2","first-page":"299","article-title":"A simplified correction of subclavian steal syndrome","volume":"75","author":"LeVeen HH","year":"1974","journal-title":"Surg"},{"key":"e_1_3_1_34_2","unstructured":"Lund RH Newkirk JB. Peritoneovenous shunting for surgical management of ascities. Contemp Surg . 1979;31-45."},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker G","year":"2006","journal-title":"Eur J Cancer"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/1097-0142(19850501)55:9<1973::AID-CNCR2820550924>3.0.CO;2-K","article-title":"Surgical and pathologic complications associated with peritoneovenous shunts in management of malignant ascites","volume":"55","author":"Souter RG","year":"1985","journal-title":"Cancer"},{"issue":"6419","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/bmj.288.6419.749","article-title":"Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts","volume":"288","author":"Tarin D","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF02303809","article-title":"Peritoneovenous shunts for palliation of the patient with malignant ascites","volume":"1","author":"Schumacher DL","year":"1994","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/1097-0142(19841115)54:10<2226::AID-CNCR2820541026>3.0.CO;2-7","article-title":"Control of malignant ascites by peritoneovenous shunting","volume":"54","author":"Gough IR","year":"1984","journal-title":"Cancer"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/bjs.1800700809","article-title":"Peritoneovenous shunts in the management of malignant ascites","volume":"70","author":"Souter RG","year":"1983","journal-title":"Br J Surg"},{"key":"e_1_3_1_41_2","first-page":"33","article-title":"Peritoneovenous shunting for malignant ascites","volume":"110","author":"Wickremesekera SK","year":"1997","journal-title":"N Z Med J"},{"issue":"6","key":"e_1_3_1_42_2","first-page":"468","article-title":"Managing ascities via Tenckhoff catheter","volume":"4","author":"Murphy M","year":"1995","journal-title":"Medsurg Nurs"},{"issue":"5","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1272\/jnms.74.355","article-title":"Peritoneovenous shunts for palliation of malignant ascites","volume":"74","author":"Mamada Y","year":"2007","journal-title":"J Nippon Med Sch"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/j.1440-1746.2006.04793.x","article-title":"Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis","volume":"22","author":"Seike M","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_1_45_2","unstructured":"Revised grading system of the Scottish Intercollegiate Guidelines Network (SIGN) www.sign.ac.uk\/guidelines\/fulltext\/50\/index.html."},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/1097-0142(19930315)71:6<2027::AID-CNCR2820710617>3.0.CO;2-C","article-title":"Intraperitoneal interferon in the management of malignant ascites","volume":"71","author":"Stuart GC","year":"1993","journal-title":"Cancer"},{"key":"e_1_3_1_47_2","first-page":"23","article-title":"Intraperitoneal recombinant alpha 2-interferon for \u2018salvage\u2019 immunotherapy in persistent epithelial ovarian cancer","volume":"12","author":"Berek JS","year":"1985","journal-title":"Cancer Treat Rev"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00000421-198204000-00064","article-title":"Human leukocyte interferon therapy for advanced ovarian carcinoma","volume":"5","author":"Einhorn N","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0277-5379(91)90467-R","article-title":"Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites","volume":"27","author":"R\u00e4th U","year":"1991","journal-title":"Eur J Cancer"},{"issue":"5","key":"e_1_3_1_50_2","first-page":"2201","article-title":"Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients","volume":"15","author":"Yamaguchi Y","year":"1995","journal-title":"Anticancer Res"},{"issue":"3","key":"e_1_3_1_51_2","first-page":"445","article-title":"Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases","volume":"16","author":"Xu L","year":"2000","journal-title":"Int J Oncol"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano S","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_3_1_53_2","first-page":"1899","article-title":"Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites","volume":"4","author":"Beattie GJ","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_54_2","first-page":"1207","article-title":"The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice","volume":"2","author":"Low JA","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0090-8258(92)90084-V","article-title":"Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3","volume":"47","author":"Buckman R","year":"1992","journal-title":"Gynecol Oncol"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1191\/026921699677473561","article-title":"Octreotide as an agent for the relief of malignant ascites in palliative care patients","volume":"13","author":"Cairns W","year":"1999","journal-title":"Palliat Med"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T10:52:24Z","timestamp":1559472744000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.4103\/0256-4947.55167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.4103\/0256-4947.55167"],"URL":"https:\/\/doi.org\/10.4103\/0256-4947.55167","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}